Stock Events

Stock Events

FibroBiologics

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

19MayExpected

Q4 2025

Next

-1.22

-1.1

-0.97

-0.85

Expected EPS

-1.1377686

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SG00.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is involved in developing therapies for various diseases, including those related to fibrosis, which directly competes with FibroBiologics' focus on fibrotic diseases and regenerative medicine.

Gilead Sciences

Gilead Sciences has a strong presence in developing treatments for fibrotic diseases, particularly in liver fibrosis, positioning it as a direct competitor in the fibrosis therapy market.

Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on treating cystic fibrosis and other diseases that involve fibrotic processes, making it a key competitor in the fibrosis therapeutic area.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, including treatments for fibrotic diseases, competing in the same biologic space as FibroBiologics.

Bristol-Myers Squibb

Bristol-Myers Squibb develops various drugs for fibrotic diseases, including NASH, which overlaps with FibroBiologics' therapeutic areas.

AbbVie works on several biologic drugs that target inflammatory and fibrotic diseases, areas that are also key focuses for FibroBiologics.

Novartis offers medications for multiple sclerosis and other chronic diseases involving fibrosis, competing in the same market as FibroBiologics.

Amgen produces biologics that treat various fibrotic conditions, directly competing with FibroBiologics in the biotechnology and pharmaceutical sectors.

Merck & Co. develops treatments for chronic diseases that can involve fibrotic complications, positioning it as a competitor in the fibrosis treatment market.

Sanofi focuses on therapies for fibrotic diseases and other chronic conditions, making it a competitor in the same therapeutic areas as FibroBiologics.

About

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Show more...

CEO

Mr. Peter O'Heeron

Employees

13

Country

United States

ISIN

US31573L2043

WKN

000A426UV

Listings

0 Comments

Share your thoughts

FAQ

What is FibroBiologics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange FibroBiologics stocks are traded under the ticker SG00.F.

When is the next FibroBiologics earnings date?▼

FibroBiologics is going to release the next earnings report on May 19, 2026.

What were FibroBiologics earnings last quarter?▼

SG00.F earnings for the last quarter are -0.85 EUR per share, whereas the estimation was -1.22 EUR resulting in a +30.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.

How many employees does FibroBiologics have?▼

As of April 26, 2026, the company has 13 employees.

In which sector is FibroBiologics located?▼

FibroBiologics operates in the Health & Wellness sector.

When did FibroBiologics complete a stock split?▼

The last stock split for FibroBiologics was on March 30, 2026 with a ratio of 1:20.

Where is FibroBiologics headquartered?▼

FibroBiologics is headquartered in Houston, United States.